Related Experiment Videos
[Multimodal therapy of high-grade gliomas in adults]
B Fazeny-Dörner1, M Piribauer, C Marosi
1Klinische Abteilung für Onkologie, Universitätsklinik für Innere Medizin I, Allgemeines Krankenhaus Wien, Austria.
Abstract:
Multimodal Therapy of High Grade Gliomas in Adults For chemotherapy of high-grade gliomas only few substances with proven efficacy are available. Today, even the newest substances are not proven to be superior to nitrosoureas. Although nitrosoureas are still considered as commonly accepted standard treatment, these results are based on studies in which response evaluation was not performed according to standardized criteria: prognostic criteria were not taken into account and statistical power of these studies is limited. However, a lot of questions remain to be dealt with and are currently under investigation in multicentric randomized studies. Therefore, patients should be encouraged to participate in prospectively randomized trials. With or after chemotherapy, supportive and palliative care including neurorehabilitation are important to improve patients' quality of life.
Insights
For high-grade gliomas in adults, few chemotherapy drugs are proven effective, with nitrosoureas remaining a standard despite study limitations. Patients should join clinical trials for better treatment options and improved quality of life through supportive care.
Area of Science:
- Oncology
- Neuroscience
Context:
- High-grade gliomas in adults present limited chemotherapy options.
- Nitrosoureas are the current standard, but evidence supporting their superiority is based on older studies with methodological limitations.
Purpose:
- To review the current landscape of chemotherapy for high-grade gliomas.
- To highlight the need for further research and patient participation in clinical trials.
Summary:
- Few chemotherapy agents demonstrate proven efficacy in high-grade gliomas.
- Newer agents have not definitively surpassed nitrosoureas, whose efficacy data is limited by non-standardized response evaluation and lack of prognostic criteria.
- Multicenter randomized trials are ongoing to address remaining questions.
Impact:
- Emphasizes the importance of patient enrollment in prospective randomized trials for advancing treatment strategies.
- Highlights the role of supportive and palliative care, including neurorehabilitation, in enhancing patient quality of life during or after chemotherapy.